SIBO is defined as bacterial colonization of the small intestine at concentrations exceeding 10⁵ CFU/mL of intestinal fluid, compared to the normal small bowel which should contain fewer than 10³ CFU/mL. The gold standard diagnosis is jejunal aspiration culture, but the practical clinical tool is the hydrogen/methane breath test. The small bowel is normally kept relatively sterile by three primary defense mechanisms: gastric acid (pH 1–3 kills most bacteria), the migrating motor complex (MMC — sweeping peristaltic contractions that clear bacteria distally every 90–120 minutes during fasting), and ileocecal valve function (preventing colonic bacteria from refluxing). When any of these fail, bacterial overgrowth results.
The clinical controversy around SIBO is substantial. Proponents (particularly Mark Pimentel's group at Cedars-Sinai) argue SIBO is underdiagnosed and drives IBS-D cases through a specific mechanism: food poisoning with CdtB toxin-producing bacteria (Campylobacter, Salmonella) triggers autoimmune damage to vinculin in enteric neurons via molecular mimicry, impairing the MMC and allowing chronic bacterial colonization of the small bowel. Critics note that breath test sensitivity and specificity vary widely, the "normal" threshold is debated, and placebo rates in trials are high — suggesting symptom-based SIBO diagnosis often captures functional disorders that improve on any intervention.
| Type | Gas Producer | Clinical Phenotype | Treatment |
|---|---|---|---|
| Hydrogen SIBO (H2-SIBO) | Bacteria (Enterobacteriaceae, Clostridia) fermenting carbohydrates → hydrogen in small bowel | Diarrhea-predominant; bloating; rapid gas production after carbohydrate intake; IBS-D phenotype | Rifaximin 550mg TID × 14 days (TARGET trial evidence); 40% responder rate vs 32% placebo |
| Methane / IMO (Intestinal Methanogen Overgrowth) | Archaea (Methanobrevibacter smithii) consuming hydrogen → methane; technically not bacteria — hence "IMO" preferred by Rome Foundation | Constipation-predominant; slow transit; bloating; methane directly slows colonic motility; IBS-C or chronic constipation phenotype | Rifaximin 550mg + neomycin 500mg dual antibiotic (Pimentel 2006); single-agent rifaximin frequently fails archaea; requires combination therapy |
| Hydrogen sulfide SIBO (H2S-SIBO) | Sulfate-reducing bacteria (Desulfovibrio spp.) producing H2S; not detected on standard H2/CH4 breath tests — requires specialized H2S breath test | Diarrhea with urgency; distinctive sulfurous gas ("rotten egg"); associated with IBD and visceral hypersensitivity; frequently missed and undertreated | Bismuth subsalicylate (Pepto-Bismol); low-sulfur diet; rifaximin may help; poorly studied; H2S breath test required for diagnosis |
The SIBO breath test measures exhaled hydrogen and methane after ingesting a carbohydrate substrate (typically lactulose 10g or glucose 75g dissolved in water). Hydrogen and methane are produced only by bacteria/archaea, not human cells — so exhaled gas reflects microbial fermentation. A rise of ≥20 ppm hydrogen above baseline within the first 90–120 minutes (before colonic fermentation should occur) indicates SIBO. Methane ≥10 ppm at any time point indicates methane SIBO/IMO.
Critical limitations: a 2017 consensus conference found sensitivity of 42–68% and specificity of 44–100% depending on protocol — the test is imperfect. False positives occur from rapid intestinal transit (colonic gas appearing "early") and from mouth bacteria (rinse well before testing). False negatives occur when bacteria produce neither hydrogen nor methane (H2S producers). Glucose is absorbed in the proximal small bowel, so it misses distal SIBO but has higher specificity; lactulose reaches the colon, providing higher sensitivity but more false positives. Pre-test requirements: 24-hour low-fermentation diet, 12-hour fast, no antibiotics for 4 weeks, no prokinetics for 3 days.
Step 1 — Identify and address underlying cause (essential for relapse prevention): The most common causes of impaired MMC (and therefore SIBO): opioid medications (most common single cause — opioids directly paralyze the MMC); proton pump inhibitors (reduce gastric acid, allowing upper GI bacterial survival); hypothyroidism (slows GI motility); prior abdominal surgery or adhesions (anatomical blind loops); systemic sclerosis or other dysmotility conditions. Without correcting the underlying cause, SIBO recurrence is near-universal within 3–6 months.
Step 2A — Antibiotics (first-line for most patients): Hydrogen SIBO: rifaximin 550mg three times daily × 14 days (TARGET trial evidence, FDA approved). Methane/IMO: rifaximin 550mg TID + neomycin 500mg TID × 14 days (Pimentel 2006 RCT showed dual therapy significantly outperformed rifaximin alone for methane-positive patients; 87% vs 33% eradication rate). Rifaximin's near-zero systemic absorption (<0.4%) makes it gut-specific with low systemic side effects — nausea and headache in ~5% of patients; C. diff risk is lower than with systemic antibiotics.
Step 2B — Elemental diet (alternative or when antibiotics fail): 14–21 day exclusive elemental diet (Vivonex, Tolerex, or similar pre-digested formula) achieves 80–91% breath test normalization by starving bacteria — monomeric nutrients are absorbed in the proximal small bowel before reaching bacterial colonies. Extremely difficult to complete: liquid only, poor taste, expensive. Often used by functional medicine practitioners for patients who prefer avoiding antibiotics or have failed multiple antibiotic courses.
Step 3 — Herbal antimicrobials (alternative to rifaximin): Herring et al. 2014 (Digestive Diseases): Candibactin-AR + Candibactin-BR (oregano oil + berberine-based herbal blend) × 4 weeks produced breath test normalization in 46% vs 34% for rifaximin — not a statistically significant difference. This suggests herbal antimicrobials are a reasonable alternative for patients avoiding pharmaceutical antibiotics, though the evidence base is considerably smaller. Allicin (from garlic) is commonly used for methane SIBO based on in vitro activity against archaea.
Step 4 — Prokinetics after treatment (critical, often neglected): After successful antibiotic treatment, initiate a prokinetic to restore MMC function and prevent relapse. Options: low-dose naltrexone (LDN) 1–4.5mg at bedtime (off-label; stimulates endogenous opioid receptor cycling, restoring MMC); low-dose erythromycin 50mg at bedtime (motilin receptor agonist, well-studied MMC stimulant); prucalopride 1–2mg (5-HT4 agonist). Herbal options: ginger root extract 500mg TID; artichoke extract. Continue prokinetics for minimum 3–6 months post-treatment.
Diet during and after treatment: Low-FODMAP diet during antibiotic treatment reduces fermentable substrate (reduces gas and symptoms, may improve treatment efficacy by starving bacteria). Avoid fiber supplements during antibiotic course — fiber feeds bacteria you're trying to eliminate. Post-treatment, phased FODMAP reintroduction as tolerated. Long-term extreme dietary restriction is not recommended — it reduces microbiome diversity and is unsustainable.
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.